Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

Running, not enrolling · Phase 3

Conditions studied: Cystic Fibrosis

In brief

The purpose of this study is to evaluate the pharmacokinetics, safety, tolerability and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants with at least 1 triple combination responsive (TCR) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Key facts

Study ID
NCT05422222
Run by
Vertex Pharmaceuticals Incorporated
People needed
210
Starts
2022-06-21
Expected to finish
2030-06-30
Last updated by the study team
2026-05-28

Who can join

Age: 1 and older, up to 11. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.